Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced the initiation of a Phase III clinical trial evaluating HB0025 in combination with chemotherapy for the first-line treatment of advanced or recurrent endometrial cancer. The in-house developed anti-PD-L1/VEGF bispecific fusion protein represents Huahai’s entry into the dual-target immuno-oncology space, leveraging synergistic “immune enhancement + anti-angiogenesis” mechanisms.
Revenue Forecast: Peak sales RMB 800 million–1.2 billion annually in China assuming 15–20% first-line advanced endometrial cancer market share; global potential $300+ million
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase III execution, clinical efficacy outcomes, and commercial potential for HB0025 in endometrial cancer. Actual results may differ due to competitive dynamics with PD-1/VEGF combinations, chemotherapy backbone selection, and reimbursement negotiations in the gynecologic oncology market.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
